Anavex Life Sciences Corp (AVXL)

[nidan7500]

Am I missing something? Not yet. But in addition review this 2017 patent app for A2-73 being used as outpatient method for treating AD. This patent shows how an outpatient service of treatments will be applied to AD patients using ERP with clinical controls unlike current treatment practices.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220180360796%22.PGNR.&OS=DN/20180360796&RS=DN/20180360796
I see the latest trials you refer to as the application/development of the same framework for treatment to SD. Once the protocol for ERP use by this trial is established then the entire practice-process is open to FDA validation. So, we look forward to the Consortium having a validated and patented tool suite including H/W, S/W , clinical methods and practices. (Cognision will probably drive this) They are then positioned to do A2-73* type treatment of future SD patients under controlled conditions which (IMO) will be licensed as a service to be applied by Dr's and staff as an outpatient w/enhanced QOL and IP. ref. how our team in AUS is doing RSD in controlled environment. This should offer QOL improvements for SD patients.

IMO, this is a demo of the strategy which Dr. M and the consortium will apply to other CNS diseases, particularly rare types where the process may be completed anywhere on the planet. If I am right, the Consortium will own a process(IP) for clinical controlled/validated treatment for CNS diseases WW. Both the process and the treatment med will be licensed.

Great strategic thinking by the Consortium team. As in Musashi, we have them surrounded and they do not even know it.BTW, the PED rumors around NYY are only rumors, wink-wink.